Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future

Area of Science:

• Immunology
• Oncology
• Cellular Therapy

Background:

• Gamma delta (γδ) T-cells are potent effector cells for cancer immunotherapy, recognizing transformed cells independently of HLA presentation.
• Two major γδ T-cell subtypes, Vδ1 and Vδ2, infiltrate tumors, with distinct roles in immune response and regulation.
• Vγ9Vδ2 T-cells, abundant in peripheral blood, recognize cancer-specific metabolites via their T-cell receptor.

Purpose of the Study:

• To review current and emerging γδ T-cell-based therapeutic strategies for cancer immunotherapy.
• To discuss the clinical prospects of Vγ9Vδ2 T-cell therapies evaluated in ongoing studies.
• To explore future therapeutic directions based on promising preclinical findings.

Main Methods:

• Review of existing literature on γδ T-cell biology and cancer immunotherapy.
• Analysis of early clinical studies involving Vγ9Vδ2 T-cell expansion, adoptive transfer, and systemic activation.
• Evaluation of preclinical data for novel γδ T-cell-based therapeutic approaches.

Main Results:

• Early Vγ9Vδ2 T-cell therapies (ex vivo expansion, adoptive transfer, phosphoantigen activation) showed limited clinical efficacy despite mild immune-related adverse events.
• Recent advancements have revitalized interest in Vγ9Vδ2 T-cells for cancer immunotherapy.
• Preclinical studies indicate significant potential for novel γδ T-cell-based strategies.

Conclusions:

• γδ T-cell immunotherapies, particularly those involving Vγ9Vδ2 T-cells, hold substantial promise for cancer treatment.
• Further clinical evaluation and development are crucial to realize the full therapeutic potential of these approaches.
• Continued research into γδ T-cell biology and therapeutic manipulation may lead to next-generation cancer immunotherapies.